• EdU Cell Proliferation Kit for RA S-Phase Studies

  2026-08-22

  The EdU Cell Proliferation Kit (TMB) converts DNA synthesis into a practical, non-radioactive absorbance readout for fibroblast-like synoviocyte studies, genotoxicity testing, and pharmacodynamic drug evaluation. Its click-chemistry workflow is especially useful for testing whether ARL4C perturbation changes S-phase entry without confusing proliferation with macrophage phenotype.

• Carvedilol: Receptor Context and Regeneration

  2026-08-21

  Carvedilol is a β-adrenergic receptor antagonist whose effects extend from cardiovascular signaling and oxidative stress inhibition to hematopoietic regeneration. This article provides a context-first framework for selecting assays, controls, concentrations, and interpretations.

• CLEC5A and ISG20: Causal Links to Atherosclerosis

  2026-08-21

  Zhang et al. integrate GEO transcriptomics, eQTL evidence, Mendelian randomization, pathway analysis, and experimental validation to distinguish atherosclerosis-associated genes from potential causal regulators. The study identifies CLEC5A and ISG20 as positively associated with atherosclerosis risk and provides the strongest functional evidence for ISG20 in macrophage lipid accumulation and plaque inflammation.

• Coumestrol, PMAIP1, and Ferroptosis in RA-FLS

  2026-08-20

  The reference study identifies a mechanistic link between Coumestrol exposure, TRIM3-dependent regulation of mitochondrial PMAIP1, and ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. Its findings suggest that redirecting abnormal FLS survival toward iron-dependent cell death can reduce both synoviocyte proliferation and inflammatory cytokine production, while also defining important limits for translation beyond the tested cell model.

• LY294002: From PI3K Mechanism to Translation

  2026-08-20

  LY294002 provides a reversible, cell-permeable way to interrogate class I PI3K biology while connecting pathway inhibition to apoptosis, autophagy, and tumor-model decisions. This thought-leadership guide translates mechanistic evidence into practical study design and strategic interpretation.

• L-Ornithine Workflows for OTC Metabolism

  2026-08-19

  L-Ornithine enables controlled studies of OTC activity, ammonia handling, and liver–brain metabolic signaling. This practical guide turns recent ornithine–astrocyte findings into preparation, assay, troubleshooting, and comparative workflow decisions.

• KDM3A–METTL16–PDK1 Axis in TKI Resistance

  2026-08-19

  The reference study identifies a coordinated epigenetic and epitranscriptomic mechanism that elevates pyruvate dehydrogenase kinase 1 (PDK1) and promotes EGFR-TKI resistance. Its findings connect KDM3A-mediated chromatin remodeling with METTL16–IGF2BP1 control of PDK1 mRNA stability, providing a mechanistic framework for biomarker development and combination treatment.

• Sulfachloropyridazine: Assays, Workflows & Applications

  2026-08-18

  Sulfachloropyridazine connects DHPS-focused mechanism studies with antimicrobial susceptibility testing, microbiome profiling, and infection-model research. This workflow-oriented guide explains how to prepare the compound, design interpretable assays, and translate the reference study’s cecal microbiota findings into stronger experimental decisions.

• NS1–DNMT1 Control of HBoV1 Replication

  2026-08-18

  A 2024 PLOS Pathogens study identifies DNMT1-dependent methylation as a regulatory layer linking human bocavirus 1 DNA replication with viral RNA processing. The work shows that HBoV1 NS1 promotes DNMT1 degradation through the ubiquitin–proteasome pathway, shifting the balance toward RNA processing and viral protein expression.

• ARL4C, Synoviocyte Proliferation, and RA Progression

  2026-08-17

  An integrated single-cell and bulk transcriptomic study identifies ARL4C as a high-expression driver in rheumatoid arthritis fibroblast-like synoviocytes, linking synoviocyte proliferation and invasion to macrophage polarization. Perturbation experiments in cells and collagen-induced arthritis rats support ARL4C as a mechanistically relevant, but not yet clinically validated, target for studying synovial inflammation and joint damage.

• Annexin V-FITC/PI: Reading Apoptosis in GBM

  2026-08-16

  The Annexin V-FITC/PI Apoptosis Assay Kit enables stage-resolved apoptosis analysis in glioblastoma models. This guide connects phosphatidylserine externalization and membrane integrity with hypoxia-driven temozolomide resistance, emphasizing how to interpret assay results mechanistically rather than treating them as a single viability percentage.

• RG7388: MDM2 Antagonism Meets p53 Biomarkers

  2026-08-15

  RG7388 is a selective MDM2 antagonist for investigating p53 pathway activation, apoptosis, and treatment response. This article connects its pharmacology with MDM1-guided chemoradiotherapy research to develop more informative, biomarker-aware oncology assays.

• IWR-1-endo: Wnt Signaling Inhibitor Workflow

  2026-08-15

  Build reproducible Wnt/β-catenin experiments with IWR-1-endo, from DMSO stock preparation and dose–response design to orthogonal β-catenin and proliferation readouts. The workflow also adapts cell-type-resolved thinking from a large atrial fibrillation single-nucleus study without overstating what that cardiovascular evidence demonstrates about Wnt biology.

• Tacrine Hydrochloride Hydrate for AD Assays

  2026-08-14

  Tacrine hydrochloride hydrate provides a practical reference tool for connecting acetylcholinesterase inhibition with cellular neuroprotection in Alzheimer’s disease research. This guide presents a metabolism-aware workflow, concentration design, assay controls, and troubleshooting strategies for using Tetrahydroaminacrine in biochemical and neurodegenerative disease models.

• Coumestrol, Ferroptosis, and RA Synoviocyte Biology

  2026-08-14

  A 2026 study identifies a TRIM3–PMAIP1 regulatory axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. The findings connect mitochondrial stress, iron accumulation, inflammatory cytokine suppression, and abnormal FLS proliferation, while highlighting important limits of translating an MH7A cell model into therapeutic development.

449 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page